Atomic Launches to Bridge the Gap Between Breakthrough MedTech Innovation and Venture-Ready Business

-Atomic launches today as a first-of-its-kind service offering for MedTech startups built to bridge the gap between breakthrough concepts and investor-re...

November 13, 2025 | Thursday | News
March Biosciences Receives FDA RMAT Designation for MB-105 CAR-T in T-Cell Lymphoma

- March Biosciences (March Bio), a clinical stage biotechnology company developing cell therapies for hard-to-treat cancers,  announced that the U.S...

November 12, 2025 | Wednesday | News
Gnome Sciences Identifies Cancer Drug That Prevented ALS in Preclinical Study

Gnome Sciences, a molecular pathology and translational research services company, announced a significant advance in the fight against ALS (amyotrophic ...

November 12, 2025 | Wednesday | News
Vascarta and CUNY Report Preclinical Breakthrough Demonstrating STO-1 Selectively Eliminates Glioblastoma Cells

Vascarta Inc., a healthspan focused, clinical stage biopharmaceutical company advancing safe, patient friendly therapies for pain, inflammation, and, in ...

November 11, 2025 | Tuesday | News
Novartis Opens Carlsbad Radioligand Therapy Manufacturing Site as Part of $23B US Investment Plan

Carlsbad location is company’s third US-based radioligand therapy (RLT) manufacturing site New site expands manufacturing footprint to meet fut...

November 11, 2025 | Tuesday | News
Merck Presents Phase 3 Data Showing Enlicitide Achieved Up to 60% LDL-C Reduction With Placebo-Like Safety

Enlicitide, designed to deliver antibody-like efficacy, has the potential to be the first approved oral PCSK9 inhibitor to lower LDL-C with a safety pr...

November 10, 2025 | Monday | Reports
Cytiva Launches Fibro dT Platform to Accelerate High-Yield mRNA Purification

Fibro dT platform offers a high-capacity solution for mRNA purification with chromatography cycle times under 15 minutes.  Sustainable pe...

November 07, 2025 | Friday | News
Normunity Doses First Patient in Phase 1 Trial of NRM-823, a First-in-Class T Cell Engager

Phase 1a/1b study will evaluate NRM-823 as monotherapy and in combination with immune checkpoint inhibition in patients with locally-advanced or metastat...

November 06, 2025 | Thursday | News
Pfizer Files Lawsuit Against Metsera and Novo Nordisk Over Breach of Merger Agreement

Pfizer Inc. announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery...

November 03, 2025 | Monday | News
ChemDiv Expands Partnership to Advance Ratutrelvir, a Rationally Designed Ritonavir-Free Mpro Inhibitor for COVID-19

ChemDiv, a global provider of integrated drug discovery solutions,  announced the extension of its Chemistry, Manufacturing and Controls (CMC) servi...

October 31, 2025 | Friday | News
Chromatin Bioscience and Purespring Therapeutics Partner to Develop Cell-Selective Synthetic Promoters for Next-Generation Gene Therapies

Chromatin Bioscience is pleased to announce an ongoing research collaboration with Purespring Therapeutics, a precision nephrology company leading the de...

October 28, 2025 | Tuesday | News
Zai Lab Reports 68% Response Rate for DLL3-Targeted ADC Zocilurtatug Pelitecan in Second-Line Small Cell Lung Cancer

- Robust responses observed in heavily pre-treated patients with a 68% ORR for 1.6 mg/kg in second-line setting -Compelling activity in patients with ...

October 27, 2025 | Monday | Reports
Cytiva Achieves ISCC PLUS Certification for Biobased Resins in Whatman Filtration Devices

Labs will soon have access to filtration products made with ISCC PLUS-certified biobased resins Certified materials enable labs to choose more sustainab...

October 24, 2025 | Friday | News
Merck’s Long-Term OGSIVEO® Data Demonstrate Durable Tumour Reduction, Sustained Symptom Relief, and Consistent Safety in Desmoid Tumour Patients

Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustai...

October 22, 2025 | Wednesday | Reports

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close